Kornimate/medical-research-clean huggingface dataset:
comparison of scapular stabilization and mobilizations in sub acromial pain syndrome

Conditions: Subacromial Impingement Syndrome

Summary: the aim of this research is to compare the effect comparison of scapular stabilization exercises and scapular mobilizations on shoulder pain, scapular kinematics, disability and functional limitations in patients with sub acromial pain syndrome randomized controlled trials done at district head quarters mirpur ajk. the sample size was 36. the subjects were divided in two groups, 18 subjects in scapular mobilization exercise group and 18 in scapular mobilization exercise therapy group. study duration was of 12 months. sampling technique applied was non probability convenient sampling technique. only 25-40 years old patient with unilateral shoulder pain lasting \>6 weeks were included. tools used in the study are nprs, spadi, worc lsst and sat.

sub acromial pain syndrome (saps), an up to date terminology (shoulder impingement syndrome ) is a common healthcare problem, especially in adult where the space directly below the acromion process and above the shoulder joint, has narrowed and patients describe pain on lateral and anterior aspect of shoulder . the estimated prevalence in the general population is 7 to 26 percent and it accounts for 44 to 65% of all shoulder problems. incidence of shoulder impingement in the us military population is 7.77 cases/1000 person-years and in uk 3 out of every 4 patient with shoulder pathologies are seeking medical treatment for saps. risk factors include repetitive activity above the shoulder, decubitus sleeping position, a hook-type acromion, smoking, muscle imbalance, bone and joint abnormalities etc. common symptoms are persistent pain without any history of trauma, difficulty reaching up behind the back, weakness in shoulder muscles, pain when the arm is raised between 70 and 120 degrees and scapular dyskinesia. * research surrounding sub acromial pain syndrome has experienced significant growth recently especially in the area of its management. physiotherapy management protocol for saps includes, postural correction exercises, neuromuscular control exercises, stretching's, manual therapy techniques of the shoulder, scapular stabilization and mobility exercises and myofacial release therapy. scapular stabilization exercises based on open and closed kinetic chain exercises to increase muscle strength and joint position awareness.

Eligibility criteria:
inclusion criteria: * ● unilateral shoulder pain lasting \>6 weeks * patients with 3/5 positive special tests (hawkins-kennedy test, painful arc test, neer test, job test, resisted external rotation test) * patients score falling above 3 on nprs exclusion criteria: * • history of surgery, fracture, or dislocation in past 6 months * traumatic onset of pain. * received steroid injections and physical therapy during the previous 6 months * bmi above 30

Keywords: scapular stabilization exercises range of motion scapular mobilization
a study of the safety and effectiveness of jnj-42160443 as add-on treatment in patients with cancer-related pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting

Summary: the purpose of this study is to compare the safety and effectiveness of jnj-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.

this is a randomized (study drug assigned by chance), double-blind (neither the physician nor the patient knows the name of the assigned drug) study to evaluate the safety and effectiveness of jnj-42160443 compared with placebo in the treatment of men and women 18 years of age or older who are terminally ill (ie, patients who are in or who are candidates for hospice or palliative \[other medical care\] care for end-of-life management) with moderate to severe, chronic, cancer-related pain that is not controlled by standard pain medications and who have a diagnosis of active cancer. the duration of the study will be approximately 62 weeks (includes screening, the 4-week double-blind phase followed by the 48-week open-label \[study doctor and patient knows the name of the assigned treatment\] extension phase and a posttreatment phase). a single dose of jnj-42160443 or matching placebo given as an (subcutaneous \[sc\]) injection under the skin during the double-blind treatment period. during the open-label period, jnj-42160443 will be given once every 4 weeks for up to 48 weeks.

Eligibility criteria:
inclusion criteria: * terminally ill cancer patients as per judgment of the investigator (eg, patients who are in or who are candidates for hospice or palliative care for end-of-life management); diagnosis of moderate to severe pain directly related to an active cancer that is not controlled by standard pain treatments. exclusion criteria:planned major surgical procedures during the double-blind treatment phase that may affect study outcomes; prior treatment with any other investigational ngf inhibitor therapy; known allergies, hypersensitivity, or intolerance to jnj-42160443 or its excipients; enrolled in any investigational study within the previous 4 weeks or 5 half-lives of the investigational drug (whichever is longer), or are currently enrolled in another investigational study at the time of screening

Keywords: moderate to severe chronic, cancer-related pain related to an active cancer cancer-related pain moderate to severe chronic pain jnj-42160443
a study to characterize access to specialty care received by american indians/alaska natives

Conditions: Specialist Referral: Neurology; Specialist Referral: Ophthalmology; Specialist Referral: Oncology

Summary: this is an observational study to define current care pathways for american indian or alaska native patients who require specialty care and potential feasibility of conducting clinical research within the existing framework. the study is designed with the flexibility to enroll patients with any indication requiring referral to one of the following specialists: neurologist, ophthalmologist, or oncologist. eligible patients will have recently (≤6 months) been referred to a specialty care provider and not yet seen a specialist (in addition to meeting the other eligibility criteria). the ppd virtual site can enroll patients from anywhere across the united states. the study will collect data to determine whether a patient was seen by a specialist, diagnosed with a specialized disease, patient characteristics potentially associated with being seen or not seen by a specialist, and the reasons/barriers why a patient was not seen by a specialist through a number of patient surveys.


Eligibility criteria:
inclusion criteria: * ability to read english at 8th grade proficiency or have a household member willing to assist in translation to complete patient surveys * self-identification as american indian or alaska native * referred to a neurologist, ophthalmologist, or oncologist for the first time within 6 months of screening and has not been seen by the specialist. exception: patients referred to an oncologist who have had a first-time visit with an oncologist but have a pending follow-up visit or pending referral visit within 6 months of screening may be included in the study. * personal landline or cell phone and/or access to internet * willingness to complete all surveys in the study and participate for 12 months exclusion criteria: * currently under the care of a specialist (neurologist, ophthalmologist, or oncologist) to whom they are being referred to by the primary care provider (i.e., to be eligible, the specialty care physician should be new to the participant) at time of screening * currently or planned to receive care that requires in participant visits for the indication requiring referral from the primary care provider (e.g., radiotherapy, chemotherapy for cancer diagnosis). exception: patients referred to an oncologist who have had a first-time visit with an oncologist but have a pending follow-up visit or pending referral visit may be included in the study.
trial of mannitol cream for pain relief after a long run

Conditions: Pain

Summary: mannitol cream has been shown clinically to be effective for pain control. to determine if this effect is worth testing on a larger scale, 170 runners will receive a sample of 25% mannitol cream to apply on one leg, and the cream base without the mannitol on the other leg following a 10 km or longer run, and for the following five days. mannitol and control legs will be chosen at random for each runner. pain scores before and after cream application will be acquired each day for each leg. means and standard deviations found will be used to determine the size of a larger study.

the hypothesis for this study is that mannitol cream will reduce post long run pain more than vehicle cream alone. in this parallel design, 170 runners who usually experience a pain level greater than 5/10 on a numerical rating scale from 0 to 10 where zero is no pain and 10 is the worst pain ever, will be given a cream containing 25% mannitol to apply on one leg and the vehicle cream to apply on the other leg. the cream assignment will be randomized, and the runner, the person supplying the cream and the person inputting the data will be blinded as to which leg received which cream. pain levels in each leg following the long run will be recorded, via an e-mail questionnaire, or, failing this, by telephone, the day of the run, and each day, for five days following the run. mean and standard deviations for pain levels will be calculated for each treatment leg, and a repeated measures anova (analysis of variance) will be done comparing the pain levels in each leg over the six days. using this information, if the nrs (numeric rating scale) pain levels differ by more than 1/10 between the two groups, a larger study will be conducted using the information gathered in this study to determine sample size.

Eligibility criteria:
inclusion criteria: either: * never ran 10 km or more, or; * nrs pain level greater than 5/10 in both legs following a 10 km or more run exclusion criteria: * no major skin allergies * no allergy to mannitol

Keywords: pain exercise muscle
does acupuncture therapy reduce the need for labor induction after postdate (week 41)

Conditions: Post-term Pregnancy (40 to 42 Weeks Gestation)

Summary: in recent years, it is accepted to induce birth at week 41 in order to reduce the risk in surplus pregnancies. it was found that after 41 weeks, there is a significant increase in pregnancy complications including meconium liquor, shoulder dystocia and fetal death in uterus. induction at 41 weeks was found to reduce the risk of complications described above, without taking the risk of cesarean section and, therefore, the recommendation of the israel society of maternal fetal medicine, is to induce birth for women who completed 41 weeks of pregnancy. induction is performed mechanically by entering a balloon to the cervix or by medicated prostaglandins and later, intravenous pitocin to most women. the process takes two to three days with about 60-70% success rate. in recent years there has been a growing awareness to use natural methods to start labor. many women tend to turn to natural medicine in order to reduce the need for conventional drugs to start labor. given the lack of research on the issue and considering the rising demand of the involvement of alternative medicine in labor induction process, the investigators decided to carry out research on this subject.

to the study will be recruited women who have completed 40 weeks of pregnancy and have not yet given birth, with proper evaluation of mother and fetus. women who are fit to participate and had given their consent, will be computerized randomized to one of three groups. research groups: 1. group who receives acupuncture treatment in order to accelerate the development of birth. 2. group who receives sham treatment - non acupuncture treatment, but a similar treatment, so that the patient is unable to know whether she is receiving a real acupuncture treatment, or the similar one, which has no effect on the patient. 3. group who does not receive any treatment and will be reviewed a week later, unless a spontaneous birth will be developed. (procedure accepted today) the study will be carried out between week 40 and week 41. during the week acupuncture treatment, sham treatment or conservative follow-up will be carried out, depending on the study group differentiation. all women who will be randomized to the treatment groups, will fill a preliminary questionnaire for acupuncture treatment. the course of treatment: during the week of study the women in the treatments groups will receive treatment every 48-72 hours, a maximum of three treatments. measures will be taken on the following week or two when the women will come to give birth.

Eligibility criteria:
inclusion criteria: 1. women past their due date (week 40) 2. proper dating of pregnancy 3. uncomplicated pregnancy 4. normal evaluation as part of the mother and fetus routine examination on week 40 5. singleton pregnancy 6. no contraindication for vaginal birth 7. no significant signs of birth exclusion criteria: 1. past cesarean section 2. women who have undergone acupuncture treatment during pregnancy 3. women who did not undergo separation membranes
adipose derived stem cell therapy for autism

Conditions: Autism

Summary: the intent of this clinical study is to answer the questions: 1. is the proposed treatment safe 2. is treatment effective in improving the disease pathology of patients with autism.

this will be an open-label, non-randomized multi-center patient sponsored study of asc implantation after liposuction using an iv delivery system. ascs will be derived from the patient's adipose-derived tissue. liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. the cells will be delivered intravenously.

Eligibility criteria:
inclusion criteria: * children between the ages of 3 and 12 years. * dsm-iv diagnosis of autistic disorder. * total score of cars ≥ 30. * parents or legal guardian willing to sign the icf. exclusion criteria: * history of prior or current dsm-iv psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), pervasive developmental disorder not otherwise specified (pdd nos), asperger's, or rett's. * history of epileptic seizure activity in the past 6 months. * autism caused by seizure disorders (active), cerebrovascular disease or brain trauma. * the global autism ratings are assessed as being absent, minimal or mild. * existing moderate or severe extrapyramidal symptoms (eps) or history of tardive dyskinesia. * active infectious disease and/or known to have tested positive for hiv, htlv, hbv, hcv, cmv (igm \> igg) and/or syphilis will have expert consultation to determine eligibility based on the patient's infectious status * enrollment in other trials in the last 3 months without agreement to discontinue them. * life expectancy \< 6 months due to concomitant illnesses. * any illness which, in the investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results * patients on chronic immunosuppressive transplant therapy * active clinical infection within one week of enrollment. * known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate. * history of cancer * parental unwillingness and/or not able to give written informed consent.

Keywords: autistic asc therapy adsc
effect of b.bifidum 900791 intake in adult with hypolactasia and lactose intolerance

Conditions: Lactose Intolerance

Summary: lactase is high in the newborn intestine, allowing him to digest the high amounts of lactose present in breastmilk. from weaning, lactase is genetically programmed to decrease, reaching residual levels in the adult. this situation occurs in 75% of the world population and is known as "adult primary hypolactasia" while the remaining 25% is "lactase persistent" i.e. maintains in adulthood lactase values similar to these of newborns. in subjects with hypolactasia, the intake of milk products can produce digestive symptoms, making that the affected individuals spontaneously reduce the consumption of these products and, therefore, their intake of calcium and proteins. in addition to lactose-free milk and exogenous lactase, a strategy for the intolerant subjects to continue consuming dairy products is, for example, to consume yogurt, due to the fact that the lactase of the yogurt bacteria continues to function in the intestine of the consumer, hydrolyzing lactose and decreasing the development of digestive symptoms. similarly, many probiotic strains, such as l. acidophilus ncfm, l. casei crl431, b. longum 401 and b. bifidum orla jensen 1424, express β-galactosidases that hydrolyze lactose, preventing its fermentation and the production of gases. the acute administration of these strains improves lactose tolerance. in addition, a recent study reported that dietary supplementation of intolerant subjects for 4 weeks with l. casei shirota and b. breve yakult reduced digestive symptoms and breath hydrogen excretion not only at the end of the period of administration of the probiotics but also 3 months after having discontinued the use of probiotics. based on this background, the aim of this study is to determine whether the regular consumption of an ice cream with the strain b. bifidum 900791 improves lactose intolerance in hypolactasic subjects, even after the suspension of the consumption of the product. to determine if this effect is due to the adaptation of the microbiota, the investigators will also evaluate changes in the composition of the microbiota and the generation of volatile fatty acids.


Eligibility criteria:
inclusion criteria: * diagnosis of hypolactasia and lactose intolerance exclusion criteria: * diarrhea * previous gastrointestinal pathologies * current or recent intake of antibiotics, anti-inflammatory drugs, laxatives or drugs interfering with intestinal transit * alterations of intestinal anatomy or function * pregnancy * chronic diseases of different etiologies (auto-immune, inflammatory, tumor, etc.).
safety, tolerability, pharmacokinetics and pharmacodynamics of esr 1150 cl in healthy subjects

Conditions: Healthy

Summary: the objective of this study was to obtain safety and tolerability data and first pharmacokinetic and pharmacodynamic data of escalating doses of esr 1150 cl.


Eligibility criteria:
inclusion criteria: * healthy male and female caucasian subjects as determined by results of screening * written informed consent in accordance with good clinical practice and local legislation given * age ≥ 18 and ≤ 50 years * broca ≥ - 20 % and ≤ + 20 % * for first part of study: extensive metabolizers of cyp2d6 and/or "spartein" type; for second part of study: poor metabolizers of cyp2d6 and/or "spartein" exclusion criteria: * any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * surgery of gastrointestinal tract (except appendectomy) * diseases of the central nervous system (such as epilepsy) or psychiatric disorders of neurological disorders * history of orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * intake of drugs with a long half-life (\> 24 hours) (≤ 1 month prior to administration or during the trial, except for oral contraceptives) * use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial except for oral contraceptives) * participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial) * smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * inability to refrain from smoking on trial days * alcohol abuse (\> 60 g/days) * drug abuse * blood donation \> 100 ml (≤ 4 weeks prior to administration or during the trial) * excessive physical activities (≤ 10 days prior to administration or during the trial) * any laboratory value outside the reference range of clinical relevance * females only: * no reliable contraception (examples of reliable contraception: oral contraceptives, 3-month injection, intrauterine device, sterilisation, condoms + spermicide) * pregnancy or breast feeding period
expanding antimicrobial stewardship

Conditions: Infection

Summary: gold standard diagnostic criteria for diagnosing acute infection in older adult patients in the emergency department do not currently exist. these patients often have atypical presentations which can complicate diagnosis and treatment. the development of an antimicrobial stewardship program for emergency department older adult patients can ultimately improve the accuracy of diagnosis and correct antimicrobial prescribing. this research study involves data collection from enrolled subjects and treating physicians. the data will be collected using a patient interview which will be answered directly by the patient or caregiver. additional surveys will be administered to the emergency department treating physician and subsequent physician. additional data will be abstracted from the emergency department chart and from additional charts that often accompanies the patient to the emergency department. a physician adjudication process will occur if there is disagreement in diagnosis between the treating emergency department physician and succeeding physician.


Eligibility criteria:
inclusion criteria: * 65 years of age exclusion criteria: * patient incarcerated * chief complaint of suicidal or homicidal ideation * patient primarily evaluated by the trauma team